Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

NEXT STORY
SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
PREV STORY
The Global Human Microbiome Therapeutics Market is expected to grow by $ 516.08 mn during 2021-2025, progressing at a CAGR of 47.79% during the forecast period
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote

Stockholm, December 24, 2018. PledPharma AB (publ) announces that the company has filed an ...

author_avatar
NASDAQ Market News

Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH

author_avatar
NASDAQ Market News

Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

author_avatar
NASDAQ Market News